New Pill-and-Shot combo aims to tame thick blood

NCT ID NCT07445893

Recruiting now Disease control Sponsor: Duan Minghui Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new pill (gecacitinib) plus a weekly injection (pegylated interferon) can help people with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to bring blood counts back to normal and ease symptoms. Thirty adults will take the combination for 24 weeks and be closely monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gecacitinib hydrochloride tablets and pegylated interferon alfa-2b
What this could lead to: If successful, this combination could offer a new first-line treatment option to control blood cell counts and reduce symptoms in polycythemia vera patients.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The combination may cause side effects like flu-like symptoms or blood cell changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYTHEMIA VERA (PV)

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.